CMS Bails Out Heart-Assist Device R&D, Covers Comparative LVAD Studies
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to grant coverage to trials investigating left-ventricular assist devices has resolved much of the financial uncertainty surrounding LVAD development in recent years
You may also be interested in...
New WorldHeart CEO Cuts Costs, Redirects Firm To California Roots
WorldHeart plans to eliminate its Ottawa operations by March 31 as part of the firm's shift from a new technology start-up to a commercially successful device manufacturer
New WorldHeart CEO Cuts Costs, Redirects Firm To California Roots
WorldHeart plans to eliminate its Ottawa operations by March 31 as part of the firm's shift from a new technology start-up to a commercially successful device manufacturer
DES Rates Sustained, CMS Exerting Price Pressures: Payment Recap
Johnson & Johnson/Cordis' efforts to raise the drug-eluting stent inpatient payment rates fell short in 2003, paving the way for the Cypher manufacturer and imminent competitor Boston Scientific (Taxus) to wage a concerted lobbying campaign this year